<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00476268</url>
  </required_header>
  <id_info>
    <org_study_id>DM/PR/033011/003/03</org_study_id>
    <nct_id>NCT00476268</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler in Patients With Moderate to Severe Persistent Asthma</brief_title>
  <official_title>A 24-week Phase III Study to Evaluate the Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler HFA 134a-pMDI in Adult Patients With Moderate to Severe Persistent Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and tolerability of the fixed combination beclometasone/formoterol in patients with&#xD;
      moderate to severe persistent asthma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the efficacy and tolerability of&#xD;
      beclometasone/formoterol single inhaler in a twice daily regimen in patients with moderate to&#xD;
      severe persistent asthma. Patients are randomised to receive either beclometasone/formoterol&#xD;
      single inhaler (total daily dose: BDP/FF 400/24 mcg) or beclometasone CFC + formoterol DPI&#xD;
      (total daily dose: BDP 1000 mcg + FF 24 mcg) or beclometasone CFC (total daily dose: BDP 1000&#xD;
      mcg) during 24 weeks of treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">January 2005</completion_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pre-dose morning PEF</measure>
    <time_frame>End of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pre-dose FEV1</measure>
    <time_frame>At clinic visits</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other spirometric parameters</measure>
    <time_frame>At clinic visits</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning and evening asthma clinical symptom scores</measure>
    <time_frame>End of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of night and/or days free of clinical symptoms</measure>
    <time_frame>End of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of rescue short-acting b2-agonists</measure>
    <time_frame>End of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma exacerbations</measure>
    <time_frame>end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety and tolerability</measure>
    <time_frame>end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">824</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>beclometasone /formoterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>beclomethasone dipropionate 100 µg plus formoterol 6 µg pMDI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Beclomethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Beclomethasone dipropionate (BecotideTM) 250 µg/unit dose pMDI aerosol via CFC propellant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formoterol powder 12 µg/unit dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Formoterol powder 12 µg/unit dose (Foradil™)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>beclomethasone/formoterol (100/6µg) pMDI</intervention_name>
    <description>Two puffs b.i.d</description>
    <arm_group_label>beclometasone /formoterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beclometasone dipropionate 250 µg/unit dose pMDI</intervention_name>
    <description>2 inhalations bid</description>
    <arm_group_label>Beclomethasone</arm_group_label>
    <other_name>BecotideTM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol powder 12 µg/unit dose</intervention_name>
    <description>2 inhalations bid</description>
    <arm_group_label>Formoterol powder 12 µg/unit dose</arm_group_label>
    <other_name>Foradil™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of moderate to severe persistent asthma (according to GINA 2002&#xD;
             guidelines)&#xD;
&#xD;
          -  FEV1 &gt; 40% and &lt; 80% of predicted normal post-bronchodilator (and at least 0.7 L&#xD;
             absolute value)&#xD;
&#xD;
          -  Patients already treated for at least 2 months with an association of inhaled&#xD;
             corticosteroids plus LABA at doses of:&#xD;
&#xD;
             750 - 1000 µg beclomethasone dipropionate or equivalent (ICSs) 24 µg formoterol or 100&#xD;
             µg salmeterol (LABAs)&#xD;
&#xD;
          -  Or patients naïve of LABA already treated for at least 2 months with inhaled&#xD;
             corticosteroids (doses as above) associated with a daily use of SABA and/or with&#xD;
             clinical symptoms &gt; 3 times in the week prior to inclusion&#xD;
&#xD;
          -  A documented positive response to the reversibility test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating females or women of childbearing potential without any efficient&#xD;
             contraception.&#xD;
&#xD;
          -  Heavy smokers defined as smoking for &gt; 10 pack years.&#xD;
&#xD;
          -  Evidence of asthma exacerbation causing an hospitalisation or requiring treatment with&#xD;
             oral/parenteral corticosteroids or evidence of symptomatic airways infection in the 4&#xD;
             weeks prior to inclusion (3 months for slow-release corticosteroids).&#xD;
&#xD;
          -  Seasonal asthma or asthma occurring only during episodic exposure to an allergen or&#xD;
             occupational chemical sensitizer.&#xD;
&#xD;
          -  Clinically significant or unstable concomitant diseases, including clinically&#xD;
             significant laboratory abnormalities.&#xD;
&#xD;
          -  Patients with an abnormal QTc interval value in the ECG test, defined as &gt; 450 msec in&#xD;
             males or &gt; 470 msec in females.&#xD;
&#xD;
          -  Evidence of asthma worsening during the week preceding randomisation (e.g. PEF&#xD;
             variability &gt; 30% during 2 consecutive days, SABA use &gt; 8 puffs/day during 2&#xD;
             consecutive days, nocturnal awakenings due to asthma symptoms during 3 consecutive&#xD;
             days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francoise Bonnet-Gonod</last_name>
    <role>Study Director</role>
    <affiliation>Chiesi Farmaceutici</affiliation>
  </overall_official>
  <results_reference>
    <citation>Huchon G, Magnussen H, Chuchalin A, Dymek L, Gonod FB, Bousquet J. Lung function and asthma control with beclomethasone and formoterol in a single inhaler. Respir Med. 2009 Jan;103(1):41-9. doi: 10.1016/j.rmed.2008.09.002. Epub 2008 Nov 1.</citation>
    <PMID>18977646</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 18, 2007</study_first_submitted>
  <study_first_submitted_qc>May 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2007</study_first_posted>
  <last_update_submitted>July 30, 2020</last_update_submitted>
  <last_update_submitted_qc>July 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Beclomethasone</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

